CA2310248A1 - Agonistes du 5-ht1f - Google Patents
Agonistes du 5-ht1f Download PDFInfo
- Publication number
- CA2310248A1 CA2310248A1 CA002310248A CA2310248A CA2310248A1 CA 2310248 A1 CA2310248 A1 CA 2310248A1 CA 002310248 A CA002310248 A CA 002310248A CA 2310248 A CA2310248 A CA 2310248A CA 2310248 A1 CA2310248 A1 CA 2310248A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- pyridine
- pyrrolo
- hydroxy
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Abstract
Cette invention concerne des agonistes du 5-HT¿1F? de formule (I), dans laquelle A-B, X et R sont tels que définis dans la description. L'invention concerne également des formulations pharmaceutiques utilisant les composés de l'invention, ainsi que des méthodes de traitement d'états associés à l'activation du 5-HT¿1F? utilisant ces composés ou ces compositions.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/970,637 US5905084A (en) | 1997-11-14 | 1997-11-14 | 5-HTIF -agonists effective in treating migraine |
US08/970,637 | 1997-11-14 | ||
PCT/US1998/024256 WO1999025348A1 (fr) | 1997-11-14 | 1998-11-13 | Agonistes du 5-ht¿1f? |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2310248A1 true CA2310248A1 (fr) | 1999-05-27 |
Family
ID=25517243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002310248A Abandoned CA2310248A1 (fr) | 1997-11-14 | 1998-11-13 | Agonistes du 5-ht1f |
Country Status (22)
Country | Link |
---|---|
US (1) | US5905084A (fr) |
EP (1) | EP0916670B1 (fr) |
JP (1) | JP2001522887A (fr) |
KR (1) | KR20010032085A (fr) |
CN (1) | CN1284874A (fr) |
AT (1) | ATE240326T1 (fr) |
AU (1) | AU1407299A (fr) |
BR (1) | BR9814188A (fr) |
CA (1) | CA2310248A1 (fr) |
DE (1) | DE69814563T2 (fr) |
DK (1) | DK0916670T3 (fr) |
EA (1) | EA200000522A1 (fr) |
ES (1) | ES2198657T3 (fr) |
HR (1) | HRP20000297A2 (fr) |
HU (1) | HUP0004317A3 (fr) |
ID (1) | ID25478A (fr) |
IL (1) | IL135634A0 (fr) |
NO (1) | NO20002408L (fr) |
PL (1) | PL340459A1 (fr) |
PT (1) | PT916670E (fr) |
TR (1) | TR200001724T2 (fr) |
WO (1) | WO1999025348A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60011269T2 (de) * | 1999-08-12 | 2005-06-23 | Nps Allelix Corp., Mississauga | Azaidole mit serotonin rezeptor affinität |
WO2001029263A1 (fr) * | 1999-10-19 | 2001-04-26 | Genaissance Pharmaceuticals, Inc. | Isogenes cible de medicament: polymorphismes dans le gene 1e du recepteur de 5-hydroxytryptamine (serotonine) |
TWI263497B (en) | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
WO2004094380A1 (fr) | 2003-04-18 | 2004-11-04 | Eli Lilly And Company | Composes (piperidinyloxy)phenyle, (piperidinyloxy)pyridinyle, (piperidinylsulfanyl)phenyle et (piperidinylsulfanyl)pyridinyle utilises comme agonistes des recepteurs 5-ht1f |
UA82711C2 (en) | 2003-09-12 | 2008-05-12 | Эли Лилли Энд Компани | Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists |
ATE370116T1 (de) | 2003-12-17 | 2007-09-15 | Lilly Co Eli | Substituierte (4-aminocyclohexen-1-yl) phenyl and (4-aminocyclohexen-1-yl) pyridinyl verbindungen als 5-ht1f agonisten |
US8030344B2 (en) * | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
CA2795062A1 (fr) | 2010-04-02 | 2011-10-06 | Colucid Pharmaceuticals, Inc. | Compositions et methodes de synthese d'agonistes des recepteurs 5-ht1f derives de la pyridinoylpiperidine |
TWI829107B (zh) | 2019-07-09 | 2024-01-11 | 美商美國禮來大藥廠 | 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體,以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990007926A1 (fr) * | 1989-01-20 | 1990-07-26 | Pfizer Inc. | 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines |
US5521196A (en) * | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
GB9423460D0 (en) * | 1994-11-21 | 1995-01-11 | Merck Sharp & Dohme | Therapeutic agents |
US5521197A (en) * | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
CZ288897A3 (cs) * | 1995-03-20 | 1998-02-18 | Eli Lilly And Company | V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje |
US5942536A (en) * | 1995-10-10 | 1999-08-24 | Eli Lilly And Company | N- 2-substituted-3-(2-aminoethyl)-1H-indol-5-YL!-Amides: new 5-HT1F agonists |
ZA979961B (en) * | 1996-11-15 | 1999-05-05 | Lilly Co Eli | 5-HT1F agonists |
-
1997
- 1997-11-14 US US08/970,637 patent/US5905084A/en not_active Expired - Fee Related
-
1998
- 1998-11-13 BR BR9814188-0A patent/BR9814188A/pt not_active Application Discontinuation
- 1998-11-13 ES ES98309321T patent/ES2198657T3/es not_active Expired - Lifetime
- 1998-11-13 TR TR2000/01724T patent/TR200001724T2/xx unknown
- 1998-11-13 AT AT98309321T patent/ATE240326T1/de not_active IP Right Cessation
- 1998-11-13 CN CN98812914A patent/CN1284874A/zh active Pending
- 1998-11-13 PL PL98340459A patent/PL340459A1/xx unknown
- 1998-11-13 CA CA002310248A patent/CA2310248A1/fr not_active Abandoned
- 1998-11-13 PT PT98309321T patent/PT916670E/pt unknown
- 1998-11-13 WO PCT/US1998/024256 patent/WO1999025348A1/fr not_active Application Discontinuation
- 1998-11-13 EP EP98309321A patent/EP0916670B1/fr not_active Expired - Lifetime
- 1998-11-13 DK DK98309321T patent/DK0916670T3/da active
- 1998-11-13 ID IDW20000837A patent/ID25478A/id unknown
- 1998-11-13 EA EA200000522A patent/EA200000522A1/ru unknown
- 1998-11-13 JP JP2000520781A patent/JP2001522887A/ja not_active Withdrawn
- 1998-11-13 AU AU14072/99A patent/AU1407299A/en not_active Abandoned
- 1998-11-13 DE DE69814563T patent/DE69814563T2/de not_active Expired - Fee Related
- 1998-11-13 HU HU0004317A patent/HUP0004317A3/hu unknown
- 1998-11-13 IL IL13563498A patent/IL135634A0/xx unknown
- 1998-11-13 KR KR1020007005209A patent/KR20010032085A/ko not_active Application Discontinuation
-
2000
- 2000-05-09 NO NO20002408A patent/NO20002408L/no not_active Application Discontinuation
- 2000-05-12 HR HR20000297A patent/HRP20000297A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20010032085A (ko) | 2001-04-16 |
DE69814563T2 (de) | 2004-04-08 |
DE69814563D1 (de) | 2003-06-18 |
TR200001724T2 (tr) | 2000-11-21 |
NO20002408L (no) | 2000-07-12 |
NO20002408D0 (no) | 2000-05-09 |
EP0916670B1 (fr) | 2003-05-14 |
HUP0004317A3 (en) | 2002-03-28 |
WO1999025348A1 (fr) | 1999-05-27 |
DK0916670T3 (da) | 2003-09-15 |
ATE240326T1 (de) | 2003-05-15 |
HRP20000297A2 (en) | 2000-12-31 |
ES2198657T3 (es) | 2004-02-01 |
EP0916670A3 (fr) | 2001-05-23 |
ID25478A (id) | 2000-10-05 |
CN1284874A (zh) | 2001-02-21 |
BR9814188A (pt) | 2000-10-03 |
HUP0004317A2 (hu) | 2001-10-28 |
PL340459A1 (en) | 2001-02-12 |
PT916670E (pt) | 2003-09-30 |
AU1407299A (en) | 1999-06-07 |
EP0916670A2 (fr) | 1999-05-19 |
EA200000522A1 (ru) | 2000-10-30 |
JP2001522887A (ja) | 2001-11-20 |
IL135634A0 (en) | 2001-05-20 |
US5905084A (en) | 1999-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5817671A (en) | 5-HT1F agonists | |
EP0708102B1 (fr) | 5-HT1F agonistes pour le traitement de la migraine | |
US5521197A (en) | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists | |
CA2694410C (fr) | Pyridinoylpiperidines utilisees comme agonistes de 5-ht1f | |
US6358972B1 (en) | 5-HT1F agonists | |
JPH08208516A (ja) | ニューロン性髄膜溢出の5−ht1fで媒介される阻害及び片頭痛の治療の方法 | |
CA2285603A1 (fr) | Agonistes 5-ht1f heteroaromatiques substitues | |
EP0978514B1 (fr) | Dérivés d'indazole comme 5-HT1F agonistes | |
EP0916670B1 (fr) | Pyrrolo-(3,2-b)pyridines et leur utilisation comme 5-HT1F agonistes | |
US6608079B1 (en) | Indole derivatives and their use as 5-HT1F agonists | |
Filla et al. | 5-HT IF-agonists effective in treating migraine | |
Filla et al. | 5-HT 1F agonists intermediates | |
CZ20001716A3 (cs) | 5-HT1F agonisté | |
EP1082958A2 (fr) | Agonistes 5-HT1F dans la douleur chronique | |
MXPA00004480A (en) | 5-ht1f | |
EP1697305B1 (fr) | Composes (4-aminocyclohexen-1-yl)phenyle et (4-aminocyclohexen-1-yl)pyridinyle servant d'agonistes de 5-ht1f | |
Audia et al. | 5-HT 1F agonists for the treatment of migraine | |
Krushinski Jr et al. | 5-HT 1F agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |